It is generally accepted that a complete biochemical response (BR) of a man’s PSA immediately after surgery is an indicator of optimal cancer control. Does this also hold true for men with lymph node invasion (LNI)? Researchers performed a single institution study of 319 men with prostate cancer and LNI who were treated with surgery [...]
ASCO GU has given us a number of interesting posters, some of which I have already written about in prior posts. Another of these posters (abstract 232) was about an analysis by Ruessel and colleagues describing cardiovascular events among men with prostate cancer using German claims data. The researchers, in a retrospective study, attempted to [...]
Another piece of information from the recent ASCO GU conference in San Francisco Researchers have found that adding statin drugs may prolong the sensitivity of abiraterone acetate (Zytiga) in men with castration-resistant prostate cancer (CRPC) To assess the effect of statins on abiraterone therapy, Dr Harshman, of the Lank Center for Genitourinary Oncology at Dana-Farber [...]
African American men get more prostate cancer and more lethal forms of prostate cancer than men of other ethnicities. We assume that a combination of genetic differences, lifestyle, nutritional and medical access were the reasons for this disparity. Understanding the role of these different possible contributors is important if we are to be able to [...]
Radium-223 (Xofigo) is a drug for men with castrate resistant metastatic prostate cancer (mCRCP) who have multiple bone metastases. Radium-223 selectively targets bone metastases by mimicking calcium, which is attracted to the bone, especially to the fast growing areas of the tumor in the bone. It emits an alpha-emitting dose of radiation, which is mostly contained [...]
I just returned, along with Malecare’s Executive Director Darryl Mitteldorf and Dr. Wendy Lebowitz, from the ASCO Genitourinary Cancers Symposium in San Francisco. The three of us often attend this meeting, but this one had a new and very special item, a research poster (abstract no. 253) that was presented by Malecare and Mitteldorf. The [...]
This afternoon I am off to the American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco. There has already been some information leaking to the media about some of the presentations that will be going on at the conference. One such “leak” is about findings from Memorial Sloan Kettering Cancer Center [...]
There has been a lot of conversation about the role of and the use of multi-parametric MRIs in the initial diagnostic stages of prostate cancer, but little is known about its potential clinical application in the use of early salvage radiotherapy after failed radical prostatectomy. In a study to exam the potential of multi-parametric MRIs [...]
Men of African origin are disproportionately affected by prostate cancer. You can read more Malecare's African American men and Prostate Cancer website, Twice As Many http://twiceasmany.org Three specific statistics tell the story. 1- In the United States, the incidence of prostate cancer is highest among men of African origin. 2- Prostate cancer mortality is highest among [...]
It is commonly known that men on Hormone Therapy (ADT) often experience many physical and psychological side effects from the treatment. Many of my posts have discussed the physical side effects, but I have not adequately explored the adverse psychological side effects that many of us experience when we are on ADT! Besides memory issues [...]
